Mercoledì dell'Oncologia | Highlights da ESMO 2024

PROGRAMMA
17.00 Saluti e Introduzione
Francesco Perrone, Massimo Di Maio
Moderatori:
Tiziana Pia Latiano (San Giovanni
Rotondo, FG)
17.05 Total neoadjuvant treatment (TNT) with
non-operative management (NOM) for
proficient mismatch repair locally
advanced rectal cancer (pMMR LARC):
first results of NO-CUT trial
Alessio Amatu (Milano)
17.15 Pembrolizumab plus chemoradiotherapy
for high risk locally advanced cervical
cancer: the randomized, double-blind,
phase III ENGOT-cx11/GOG-3047/
KEYNOTE-A18 STUDY
Domenica Lorusso (Milano)
17.25 Amivantamab plus FOLFOX or FOLFIRI
in metastatic colorectal cancer:
Results from OrigAMI-1,
an open-label, phase Ib/II study
Filippo Pietrantonio (Milano)
17.35 -18.00 Q&A
18.00 The Rome trial from histology to target:
The road to personalize targeted
therapy and immunotherapy.
Andrea Botticelli (Roma)
18.10 A randomized phase II study to evaluate
the efficacy and safety of androgen
deprivation therapy (ADT) vs chemotherapy
(CT) in patients with recurrent and/
or metastatic, androgen receptor (AR)
expressing, salivary gland cancer
Laura Deborah Locati (Pavia)
18.20 Trastuzumab deruxtecan (T-DXd) in
patients (pts) with HER2+ advanced/
metastatic breast cancer (mBC) with or
without brain metastases (BM):
DESTINYBreast-12 primary results
Paola Zagami (Milano)
18.30 A randomized phase III trial of neoadjuvant
durvalumab plus chemotherapy
followed by radical cystectomy and
adjuvant durvalumab in muscle-invasive
bladder cancer (NIAGARA)
Chiara Ciccarese (Roma)
18.40 - 19.00 Q&A